Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes.

"Declarations Ethics approval and consent to participateAll animals were kept according to the Guidelines on the Use of Animals in Research and studies performed in compliance with the University of Bristol’s guidelines and the Animal (Scientific Procedure) Act 1986 under licences approved by UK Home Office. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by a University of Bristol PhD studentship, a Medical Research Council grant (MR/T031921/1, M.G.), Ministry of Higher Education and Scientific Research, Libya (368477, H.E.E.), an Academy of Medical Sciences Starter Grants for Clinical Lecturers (SGL021\1092) and a Kidney Research UK Innovation Grant (IN_004_20190305, M.J. B.), a Kidney Research UK Intercalation Degree Award (ID_008_20170331, E.J.W), a Kidney Research UK project grant (RP_031_20180306, M.C.), a Diabetes UK project grant (18/0005795 R.R.), a BHF project grant (PG/16/35/32139, Y.Q.), an NIH (R01AR055670, Y.Y), a Medical Research Council, Grant (MR/ P003214/1, K.A.), a Wellington Research Fund Grant (No.217883, O.V.Z.)."